IBS is a chronic disorder characterized by abdominal pain or discomfort associated with altered bowel function for at least three months, according to the Rome III criteria. Patients often experience relapse of symptoms over time.

The global Irritable Bowel Syndrome (IBS) Therapeutics market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Irritable Bowel Syndrome (IBS) Therapeutics volume and value at global level, regional level and company level. From a global perspective, this report represents overall Irritable Bowel Syndrome (IBS) Therapeutics market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Irritable Bowel Syndrome (IBS) Therapeutics in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Irritable Bowel Syndrome (IBS) Therapeutics manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Abbott Laboratories
Synergy Pharmaceuticals
Sucampo Pharmaceuticals
Valeant Pharmaceuticals International
Ardelyx
Astellas Pharma
Novartis
GlaxoSmithKline
Ironwood Pharmaceuticals

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
Blautix (Strain)
Bekinda (IBS-D)
SYN-010
Tenapanor

Segment by Application
Hospital
Research